AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after
Morphic Therapeutic has lost Johnson & Johnson's Janssen Pharma as a partner, following the termination of an alliance to develop drugs targeting integrins first agreed in 2019.
Two top pharma companies have exited the UK's voluntary medicines pricing agreement in protest at what the industry has said is a "punitive" system of revenue clawbacks, casting doubt on th
